File Download

There are no files associated with this item.

Supplementary

Conference Paper: Comparative effectiveness and cost-effectiveness assessment of erlotinib vs. gefitinib in first-line treatment of EGFR activating mutation positive non-small cell lung cancer for Hong Kong

TitleComparative effectiveness and cost-effectiveness assessment of erlotinib vs. gefitinib in first-line treatment of EGFR activating mutation positive non-small cell lung cancer for Hong Kong
Authors
Issue Date2012
PublisherISPOR.
Citation
The 5th Asia-Pacific Conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Taipei, Taiwan, 2-4 September 2012. How to Cite?
DescriptionPoster presentation: article no. 29992
Persistent Identifierhttp://hdl.handle.net/10722/165598

 

DC FieldValueLanguage
dc.contributor.authorLee, VWY-
dc.contributor.authorLee, VHF-
dc.contributor.authorSchwander, B-
dc.date.accessioned2012-09-20T08:20:46Z-
dc.date.available2012-09-20T08:20:46Z-
dc.date.issued2012-
dc.identifier.citationThe 5th Asia-Pacific Conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Taipei, Taiwan, 2-4 September 2012.-
dc.identifier.urihttp://hdl.handle.net/10722/165598-
dc.descriptionPoster presentation: article no. 29992-
dc.languageeng-
dc.publisherISPOR. -
dc.relation.ispartofISPOR Asia-Pacific Conference 2012-
dc.titleComparative effectiveness and cost-effectiveness assessment of erlotinib vs. gefitinib in first-line treatment of EGFR activating mutation positive non-small cell lung cancer for Hong Kong-
dc.typeConference_Paper-
dc.identifier.emailLee, VHF: vhflee@hku.hk-
dc.identifier.authorityLee, VHF=rp00264-
dc.identifier.hkuros210325-
dc.publisher.placeTaiwan-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats